Bolt Projects Stock Jumps 28.9% on $4.25M Share and Warrant Offering

Introduction

Bolt Projects Holdings Inc (NASDAQ: BSLK) is a material solutions company that develops nature-inspired biomaterials for the fashion and beauty industries. Founded in 2009, the company utilizes biotechnology and artificial intelligence to create sustainable alternatives to petroleum-based polymers and non-biodegradable materials.

Corporate structure and experience

Bolt Projects employs between 11 and 50 individuals, bringing together expertise in biotechnology, materials science, and supply chain management. Founder and CEO Dan Widmaier continues to lead the organization post-merger with Golden Arrow Merger Corp. The company holds 77 granted patents and has 109 pending patent applications, reflecting 14 years of research and development. The scientific leadership team includes CTO David Breslauer, PhD.

Biomaterials by SHAHBAZ SHAIKH

Developments and news

On August 14, 2024, Bolt Threads completed its merger with Golden Arrow Merger Corp and began trading as Bolt Projects Holdings Inc under the ticker symbol BSLK. On August 14, 2025, the company entered into a securities purchase agreement to issue 913,979 shares of common stock at $4.65 per share, as well as pre-funded warrants at $4.6499 per warrant. This transaction aims to raise approximately $4.25 million before expenses, with an expected closing date of August 15, 2025.

As of August 15, 2025, shares of BSLK closed at $10.9596, representing a 28.94% increase, with a trading volume of 3,149,905 shares on the Nasdaq Stock Market.

Financial and strategic analysis

Bolt Projects has a market capitalization of $17.53 million and an enterprise value of $29.56 million. For the trailing twelve months, the company reported revenue of $2.77 million, with a net loss of $10.41 million and diluted earnings per share of -$5.05. The company’s price-to-sales ratio is 6.32, and its enterprise value-to-revenue ratio is 10.67. As of the most recent quarter, the total cash balance was $1.01 million, and the levered free cash flow was $1.85 million. No forward or trailing P/E ratio is available due to negative earnings.

The prospectus filed on August 14, 2025 (Form 424B3) indicates that net proceeds from the securities offering will primarily fund general corporate purposes, including working capital. Investors should consider the potential for shareholder dilution that may result from the issuance of shares and warrants.

Market position and industry context

Operating within the biotechnology research sector, Bolt Projects targets high-volume consumer markets in fashion and beauty, focusing on sustainability and biodegradability as key differentiators. With a beta of 0.17, BSLK has exhibited lower volatility relative to the S&P 500. The company’s flagship biomaterial, b-silk™, is a fully biodegradable protein polymer designed to replace silicone elastomers in beauty formulations.

tl;dr

On August 15, 2025, BSLK shares closed at $10.9596 (+28.94%) with 3.15 million shares traded. The company filed a Form 424B3 on August 14, 2025, to issue 913,979 shares and pre-funded warrants at $4.65 each, targeting $4.25 million in gross proceeds for working capital. The offering is set to close on August 15, 2025.